

14<sup>th</sup> November 2023

To  
The Corporate Relations Department  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001.

Dear Sir/Madam,

**Sub: Submission of Un-Audited Financial Results under regulation 30 and 33 of SEBI (LODR) Regulations, 2015.**

**Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH**

\*\*\*\*\*

This is to inform you that the Board of Directors of the Company at its meeting held on this day i.e. 14<sup>th</sup> November 2023 has, inter alia, approved Un-Audited Financial Results for the Second Quarter and Half year ended on 30<sup>th</sup> September, 2023 as recommended by the Audit Committee and reviewed by the Statutory Auditors.

Further please find enclosed herewith the following documents in terms of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015:

1. Un-Audited Financial Results of the Company for the Second Quarter and Half year ended on 30<sup>th</sup> September, 2023.
2. Statement of Assets and Liabilities of the Company for the Second Quarter and Half year ended on 30<sup>th</sup> September, 2023.
3. Cash flow Statement Results of the Company for the Second Quarter and Half year ended on 30<sup>th</sup> September, 2023.
4. Limited Review Report for the Un-Audited Standalone Financial Results issued for the Second Quarter and Half year ended on 30<sup>th</sup> September, 2023.

The meeting commenced at 03.00 P.M. and concluded at 04.30 P.M.

This is for your information and necessary records.

Thanking you,

Yours faithfully,  
**For Oxygenta Pharmaceutical Limited**  
(Formerly known as S.S. Organics Ltd.)

**Name: Sai Sudhakar Vankineni**

Designation: Managing Director

DIN.: 00733001

---

**OXYGENTA PHARMACEUTICAL LIMITED** (Formerly known as S.S ORGANICS LIMITED)

(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.

Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038



**OXYGENTA PHARMACEUTICAL LIMITED**

(Formerly Known as S. S. ORGANICS LIMITED)

CIN : L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: Plot no: 43, Sy no. 55 to 58, The Park View 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500032

Website: <http://oxygentapharma.com/>, Email Ids: [md@oxygentapharma.com](mailto:md@oxygentapharma.com), [cs@oxygentapharma.com](mailto:cs@oxygentapharma.com), Phone Number: 040- 23355938

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2023**


(Rupees in Lakhs except for EPS)

S. No	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income from Operations</b>						
	(a) Net Sales/Income from Operations (net of excise duty)	1,307.59	686.39	605.65	1,993.98	1,494.96	3,098.75
	(b) Other Operating Income	0.12	-	-	0.12	-	1.78
	<b>Total income from operations (net)</b>	<b>1,307.71</b>	<b>686.39</b>	<b>605.65</b>	<b>1,994.10</b>	<b>1,494.97</b>	<b>3,100.52</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	1,167.65	808.80	504.86	1,976.45	1,265.54	2,812.61
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work- in-progress and stock-in-trade	(13.69)	(107.07)	(112.73)	(120.76)	(189.94)	(463.48)
	(d) Direct Manufacturing Expenses	298.64	294.32	292.92	592.96	536.38	1,172.55
	(e) Employee benefit expense	32.59	17.80	28.70	50.39	43.15	124.23
	(f) Finance Costs	34.10	29.41	9.98	63.51	34.89	148.75
	(g) Depreciation and amortisation expense	83.40	50.00	40.00	133.40	80.00	205.18
	(h) Other expenses	20.00	36.11	41.80	56.11	94.23	164.53
	<b>Total expenses</b>	<b>1,622.68</b>	<b>1,129.37</b>	<b>805.53</b>	<b>2,752.05</b>	<b>1,864.25</b>	<b>4,164.36</b>
<b>3</b>	<b>Profit from operations before other income and exceptional items (1-2)</b>	<b>(314.97)</b>	<b>(442.99)</b>	<b>(199.88)</b>	<b>(757.95)</b>	<b>(369.28)</b>	<b>(1,063.83)</b>
<b>4</b>	<b>Other income</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit from ordinary activities before</b>	<b>(314.97)</b>	<b>(442.99)</b>	<b>(199.88)</b>	<b>(757.95)</b>	<b>(369.28)</b>	<b>(1,063.83)</b>
<b>6</b>	<b>Exceptional (expenses)/income</b>	<b>(3.02)</b>	<b>(12.89)</b>	<b>(33.70)</b>	<b>(15.91)</b>	<b>(33.70)</b>	<b>(73.43)</b>
<b>7</b>	<b>Profit / (Loss) from ordinary activities before tax</b>	<b>(317.99)</b>	<b>(455.88)</b>	<b>(233.58)</b>	<b>(773.86)</b>	<b>(402.97)</b>	<b>(1,137.27)</b>
<b>8</b>	<b>Tax (expense)/credit</b>	-	-	-	-	-	-
	Current Tax						
	Deferred Tax	(1.99)	-	-	(1.99)	-	19.83
<b>9</b>	<b>Net Profit / (Loss) from ordinary activities after tax</b>	<b>(316.00)</b>	<b>(455.88)</b>	<b>(233.58)</b>	<b>(771.87)</b>	<b>(402.97)</b>	<b>(1,157.10)</b>
<b>10</b>	<b>Extraordinary items (net of tax expense)</b>	-	-	-	-	-	-
<b>11</b>	<b>Net Profit / (Loss) for the period (11+ 12)</b>	<b>(316.00)</b>	<b>(455.88)</b>	<b>(233.58)</b>	<b>(771.87)</b>	<b>(402.97)</b>	<b>(1,157.10)</b>
<b>12</b>	<b>Other Comprehensive Income</b>	-	-	-	-	-	-
<b>13</b>	<b>Total Comprehensive Income</b>	<b>(316.00)</b>	<b>(455.88)</b>	<b>(233.58)</b>	<b>(771.87)</b>	<b>(402.97)</b>	<b>(1,157.10)</b>
<b>14</b>	<b>Share of Profit/(loss) of associates</b>	-	-	-	-	-	-
<b>15</b>	<b>Minority interest</b>	-	-	-	-	-	-
<b>16</b>	<b>Paid-up equity share capital (face value Rs. 10/-)</b>	<b>3,348.35</b>	<b>3,348.35</b>	<b>1,420.13</b>	<b>3,348.35</b>	<b>1,420.13</b>	<b>1,420.13</b>
<b>17.i</b>	<b>Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):</b>						
	(a) Basic	(0.87)	(1.65)	(1.64)	(2.52)	(2.84)	(8.15)
	(b) Diluted	(0.76)	(1.65)	(1.64)	(2.41)	(2.84)	(8.15)
<b>17.ii</b>	<b>Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):</b>						
	(a) Basic	(0.87)	(1.65)	(1.64)	(2.52)	(2.84)	(8.15)
	(b) Diluted	(0.76)	(1.65)	(1.64)	(2.41)	(2.84)	(8.15)

**NOTES:**

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 14th November, 2023 at Corporate office, Plot no: 43, Sy no. 55 to 58, The Park View 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500032.
- The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparison.

Date: 14/11/2023  
Place: Hyderabad




For and on behalf of the Board of Directors  
OXYGENTA PHARMACEUTICAL LIMITED  
(Formerly Known as S. S. ORGANICS LIMITED)

*V sai sudhakar*  
SAI SUDHAKAR VANKINENI  
Managing Director  
DIN :00733001



<b>OXYGENTA PHARMACEUTICAL LIMITED</b>			
<b>(Formerly Known as SS Organics Limited)</b>			
<b>Statement of Assets and Liabilities as at 30th September 2023</b>			
		<b>(Rupees in Lakhs)</b>	
<b>Particulats</b>		<b>As at</b>	<b>As at</b>
		<b>30 September 2023</b>	<b>31 March 2023</b>
		<b>(Un-Audited)</b>	<b>(Audited)</b>
<b>A</b>	<b>Assets</b>		
(1)	<b>Non-current assets</b>		
	Property, plant and equipment	2,973.08	2,791.34
	Capital work-in-progress	2.25	-
	Intangible assets	-	-
	Financial assets	-	-
	Investments	4.94	4.94
	Loans	41.97	41.97
	Trade Receivables	116.00	39.66
	Others Financial assets	47.93	47.93
	Deferred tax assets, net	-	-
	<b>Total non-current assets</b>	<b>3,186.16</b>	<b>2,925.85</b>
(2)	<b>Current assets</b>		
	Inventories	1,270.01	1,170.51
	Financial assets		
	Investments	-	-
	Trade receivables	1,626.67	1,015.97
	Cash and cash equivalents	0.72	1.75
	Other balances with banks	8.00	8.87
	Loans	-	-
	Others Financial assets	-	-
	Other current assets	324.72	303.52
	<b>Total current assets</b>	<b>3,230.12</b>	<b>2,500.62</b>
	<b>Total assets</b>	<b>6,416.29</b>	<b>5,426.47</b>
<b>B</b>	<b>Equity and Liabilities</b>		
	<b>Equity</b>		
	Equity share capital	3,348.35	1,420.13
	Other equity	(5,847.89)	(6,040.13)
	Money received against Share Warrants	56.25	-
	<b>Total equity</b>	<b>(2,443.29)</b>	<b>(4,620.00)</b>
	<b>Liabilities</b>		
(1)	<b>Non-current liabilities</b>		
	Financial Liabilities		
	Borrowings	4,744.52	6,302.18
	Lease Liabilities		
	Trade payables	-	-
	- total outstanding dues of micro enterprises and small ente	-	-
	- total outstanding dues of creditors other than micro enterprises and small enterprises	315.35	306.51
	Provisions	314.14	290.14
	Deferred Tax Liabilities	163.95	165.94
	Other Non current liabilities	-	-
	<b>Total Non current liabilities</b>	<b>5,537.96</b>	<b>7,064.77</b>
(2)	<b>Current liabilities</b>		
	Financial Liabilities		
	Borrowings	694.68	497.17
	Lease Liabilities		
	Trade payables	-	-
	-total outstanding dues of micro enterprises and small enterprise	-	-
	-total outstanding dues of Creditors otherthan micro enterprises and small enterprise	2,532.14	2,377.95
	Other financial liabilities		
	Provisions	48.77	52.21
	Other current liabilities	46.02	54.38
	Income tax liabilities(net)	-	-
	<b>Total current liabilities</b>	<b>3,321.62</b>	<b>2,981.71</b>
	<b>Total liabilities</b>	<b>8,859.58</b>	<b>10,046.48</b>
	<b>Total equity and liabilities</b>	<b>6,416.29</b>	<b>5,426.47</b>



For and on behalf of the Board of Directors of  
OXYGENTA PHARMACEUTICAL LIMITED  
(Formerly Known as SS Organics Limited)  
CIN: L24110TG1990PLC012038

*Sai Sudhakar*


SAI SUDHAKAR VANKINENI  
Managing Director  
DIN :00733001

Place: Hyderabad  
Date: 14/11/2023



**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)  
Cash Flow Statement for the Half Year Ended 30th September, 2023

Particulars	(Rupees in Lakhs)	
	For the Half Year ended 30 September 2023	For the year ended 31 March 2023
<b>I. Cash flows from operating activities</b>		
<b>Profit before tax</b>	(773.86)	(1,137.27)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>	-	-
Depreciation of tangible assets	133.40	205.18
Amortisation of intangible assets	-	-
Finance income (including fair value change in financial instruments)	(0.12)	(0.50)
Dividend income from mutual funds	-	-
Finance costs (including fair value change in financial instruments)	63.51	148.75
Re-measurement losses on defined benefit plans	-	-
<b>Operating profit before working capital changes</b>	(577.07)	(783.84)
<i>Changes in working capital:</i>	-	-
Adjustment for (increase)/decrease in operating assets	-	-
Trade receivables - Non current	(76.33)	(2.85)
Trade receivables - current	(610.69)	(858.38)
Inventories	(99.50)	(442.20)
Loans - Non current	-	-
Loans - current	-	-
Other financial assets - current	-	-
Other assets - current	(21.20)	(248.62)
Other assets - non current	-	(2.41)
Adjustment for (increase)/decrease in operating liabilities	-	-
Trade payables	351.71	2,120.67
Other financial liabilities - current	(11.80)	54.28
Other current liabilities	-	-
Provisions - Non Current	(1.99)	19.83
<b>Cash generated from operations</b>	(1,046.88)	(143.54)
Interest Paid	-	-
Deferred Taxes/ Income taxes paid/charged	1.99	(19.83)
<b>Net cash generated from/(used in) operating activities</b>	(1,044.89)	(163.37)
<b>II. Cash flows from investing activities</b>		
Purchase of property, plant and equipment and intangibles (including capital work in progress)	(317.38)	(964.50)
(Investments in)/ redemption of bank deposits (having original maturity of more than three months) - net	-	-
Dividend received on mutual funds	-	-
Interest received (finance income)	0.12	0.50
<b>Net cash used in investing activities</b>	(317.26)	(963.99)
<b>III. Cash flows from financing activities</b>		
Proceeds from Share Capital	2,948.58	-
Proceeds from/(repayment of) long-term borrowings, net	(1,524.82)	1,271.17
Interest paid	(63.51)	(148.75)
<b>Net cash provided by financing activities</b>	1,360.25	1,122.41
<b>Net increase in cash and cash equivalents (I+II+III)</b>	(1.90)	(4.95)
Cash and cash equivalents at the beginning of the year	10.62	15.57
<b>Cash and cash equivalents at the end of the year (refer note below)</b>	8.72	10.62
<b>Note:</b>		
<b>Cash and cash equivalents comprise:</b>		
Cash on hand	0.05	0.02
Balances with banks:	-	-
- in current accounts & Deposits	8.67	10.60
	8.72	10.62



For and on behalf of the Board of Directors of  
OXYGENTA PHARMACEUTICAL LIMITED  
(Formerly Known as SS Organics Limited)  
CIN: L24110TG1990PLC012038

*Sai Sudhakar*

SAI SUDHAKAR VANKINENI  
Managing Director  
DIN :00733001

Place: Hyderabad  
Date: 14/11/2023






**A.M REDDY & D.R REDDY**  
**Chartered Accountants**

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of  
OXYGENTA PHARMACEUTICAL LIMITED (Formerly Known as S. S. Organics Limited)  
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015, as amended**

To,  
The Board of Directors,  
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended and Six months ended September 30, 2023 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 | Phone No: 08554-231666  
B.O H.No 3-6-640/11C, Fourth Floor, Street No 9, Himayy Nagar , Hyderabad 500 029 | Phone No : 040-40077393  
Mobile No: 9848032382 Email: D.R.Reddy1999@yahoo.com



obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A.M REDDY & D.R REDDY**

Chartered Accountants

Firms Registration No: 009068S



D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 23209211BGYWMZ1803

Place: Hyderabad

Date: November 14, 2023